Viking Therapeutics, Inc. (VKTX)
NASDAQ
Delayed Data
Oct 23, 2026, 01:30 PM
Day's Range
24.3652 wk Range
24.36Overview - VKTX - Viking Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
2.80B
P/E (Trailing)
-8.35
P/E (Forward)
-6.05
PEG Ratio
-0.09
Price / Book
7.61
EV / EBITDA
-7.14
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-51.86%
Return on Equity
-88.85%
Ownership
Shares Outstanding
116.65M
Float
113.73M
Short % of Shares Outstanding
21.44%
Held by Insiders
2.83%
Held by Institutions
60.59%
Price stats
Beta
0.64
50-Day Avg
32.73
200-Day Avg
32.96
Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - VKTX - Viking Therapeutics, Inc.
Peers - VKTX - Viking Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- VKTXNASDAQViking Therapeutics, Inc.3.38BMarket Cap-31.78%52-week change-8.36P/E (Trailing)0.00%Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)32.26%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - VKTX - Viking Therapeutics, Inc.
About
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
